Nutrióse, a prebiotic low-digestible carbohydrate, stimulates gut mucosal immunity and prevents TNBS-induced colitis in piglets

Inflammatory Bowel Diseases

Volumn 16, Issue 5, 2010, Pages 783-794

  Pouillart, Philippe R ^a   Dépeint, Flore ^a   Abdelnour, Afif ^a   Deremaux, Laetitia ^b   Vincent, Odile ^c   Mazière, Jean Claude ^c   Madec, Jean Yves ^a   Chatelain, Denis ^c   Younes, Hassan ^a   Wiis, Daniel ^b   Saniez, Marie Hélène ^b   Dupas, Jean Louis ^c  

^a INSTITUT POLYTECHNIQUE LASALLE BEAUVAIS   (France)

^b Roquette Freres   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Colon; Fibers; Inflammatory bowel disease; Low digestible carbohydrate; Pig; Tnbs model

Indexed keywords

DNA 16S; IMMUNOGLOBULIN A; INTERLEUKIN 10; NUTRIOSE; PREBIOTIC AGENT; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG; DEXTRIN; SECRETORY IMMUNOGLOBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BIOLOGICAL MONITORING; CALORIC INTAKE; COLITIS; COLON BIOPSY; CONTROLLED STUDY; DIGESTION; DIGESTIVE TRACT ENDOSCOPY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROINTESTINAL MUCOSA; HEMATOCHEZIA; IMMUNOGLOBULIN PRODUCTION; IMMUNOSTIMULATION; INTESTINE TRANSIT TIME; MALE; MICROFLORA; MUCOSAL IMMUNITY; NONHUMAN; OLIGONUCLEOTIDE PROBE; PIGLET; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; TH2 CELL; WEIGHT REDUCTION; ANIMAL; CARBOHYDRATE DIET; CHEMICALLY INDUCED DISORDER; CYTOLOGY; IMMUNOLOGY; IMMUNOMODULATION; INTESTINE MUCOSA; NEWBORN; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWINE;

ANIMALS; ANIMALS, NEWBORN; COLITIS; DEXTRINS; DIETARY CARBOHYDRATES; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; IMMUNOMODULATION; INTESTINAL MUCOSA; MALE; PREBIOTICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SWINE; TRINITROBENZENESULFONIC ACID;

EID: 77950639131     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21130     Document Type: Article

References (58)

1. Graff LA, Walker JR, Lix L, et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol. 2006;4:1491-1501.
2. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut. 2001;48:132-135.
3. Shanahan F. Nutrient tasting and signaling mechanisms in the gut. V. Mechanisms of immunologic sensation of intestinal contents. Am J Physiol Gastrointest Liver Physiol. 2000;278:G191-196.
4. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005;54:242-249.
5. Fabia R, Willen R, Ar'Rajab A, et al. Acetic acid-induced colitis in the rat: a reproducible experimental model for acute ulcerative colitis. Eur Surg Res. 1992;24:211-225.
6. Madsen KL. Inflammatory bowel, disease: lessons from the IL-10 gene-deficient mouse. Clin Invest Med. 2001;24:250-257.
7. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lattis secreting interleukin-10. Science. 2000;289: 1352-1355.
8. Ainsworth MA, Brynskov J. [Anti.-TNF-alpha antibody treatment of patients with active ulcerative colitis.] Ugeskr Laeger. 2007;169:789-791.
9. Oudkerk Pool M, Bouma G, Meuwissen SG, et al. Serological markers to differentiate between ulcerative colitis and Crohn's disease. J Clin Pathol. 1995;48:346-350.
10. Borruel N, Carol M, Casellas F, et al. Increased mucosal tumour necrosis factor alpha production in. Crohn's disease can. be downregulated ex. vivo by probiotic bacteria. Gut. 2002;51:659-664.
11. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 2001;81:1031-1064.
12. Cummings JH, Rombeau JL, Sakata T (eds.). Physiological and clinical aspects of short-chain fatty acids. Cambridge, UK: Cambridge University Press; 2004.
13. Pouillart PR. Role of butyric acid and its derivatives in the treatment of colorectal, cancer and hemoglobinopathies. Life Sci. 1998;63: 1739-1760.
14. Lefranc-Millot C. NUTRIOSE(R) 06: a useful soluble dietary fibre for added nutritional value. Nutr Bull. 2008;33:234-239.
15. van den Heuvel EG, WlIs D, Pasman WJ, et al. Dietary supplementation of different doses of NUTRIÓSE FB, a fermentable dextrin, alters the activity of faecal, enzymes in healthy men. Eur J Nutr. 2005 ;44: 445-451.
16. Vermorel M, Coudray C, WiIs D, et al. Energy value of a low-digestible carbohydrate, NUTRIÓSE FB, and its impact on magnesium, calcium and zinc apparent absorption and retention in healthy young men. Eur J Nutr. 2004;43:344-352.
17. Pasman W, WiIs D, Saniez MH, et al. Long-term gastrointestinal tolerance of NUTRIÓSE FB in healthy men. Eur J Clin Nutr. 2006;60: 1020-1034.
18. Guarner F. Inulin and oligofructose: impact on. intestinal diseases and disorders. Br J Nutr. 2005;93:S61-65.
19. 19. Cherbut C, Michel C, Lecannu G. The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. J Nuti: 2003;133:21-27. (Pubitemid 36070571)
20. Elson CO, Sartor RB, Tennyson GS, et al. Experimental models of inflammatory bowel disease. Gastroenterology. 1995;109:1344-1367.
21. Appleyard CB, Wallace JL. Reactivation of hapten-Induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol. 1995:269: G 119-125.
22. Ameno CK, Adjei AA, Harrison EK, et al. Prophylactic effect of dietary glutamkie supplementation in interleukin 8 and tumour necrisis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut. 1997;41:487-493.
23. Anton PM, Gay J, Mykoniatis A, et al. Corticotropin-releasing hormone (CRH) requirement in. Clostridium difficile toxin A-mediated intestinal inflammation. Proc Natl Acad Sci USA. 2004;101:8503-8508.
24. Lefranc-Millot C, WiIs D, Henry J, et al. NUTRIÓSE, a resistant dextrin, and MALTISORB, a sugar alcohol, two key products for healthy diets and obesity management. Obes Rev. 2006;7;269.
25. Cook SI, Sellin JH. Review article: short chain fatty acids in health and disease. Aliment Pharmacol Ther. 1998;12:499-507.
26. Lefranc-Millot C, WiIs D, Neut C, et al. Effects of a soluble fiber with excellent tolerance, Nutriose (R) 06, on the gut ecosystem; a review. Proc. Dietary Fiber Conf. 2006;P34.
27. 27. Suzuki A, Mitsuyama K, Koga H, et al. Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study. Nutrition. 2006;22:76-81. (Pubitemid 43175788)
28. Bengmark S. Bioecological control of inflammatory bowel disease. Clin Nutr. 2007;26:169-181.
29. 29. Swidsinski A, Loening-Baucke V, Vaneechoutte M, et al. Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal, flora. Inflamm Bowel Dis. 2008;14:147-161. (Pubitemid 351288036)
30. Korzenik JR. Case closed? Diverticulis: epidemiology and fiber. J Clin Gastroenterol. 2006;40:S 112-116.
31. Scheppach W, Christi SU, Bartram HPP, et al. Effects of short-chain fatty acids on the inflammed colonic mucosa. Scand J Gastroenterol Suppl. 1997;222:53-57.
32. Sagar P, Macfie J. Pouchitis, colitis and deficiencies of fuel. Clin Nutr. 1995;14:13-16.
33. Gibson PR. Ulcerative colitis: an epithelial disease? Bailliere Clin Gastroenterol. 1997; 11:17-33.
34. de Oliveira-Neto JP, de Aguilar-Nascimento JE. Intraluminal irrigation with fiber improves mucosal, inflammation and atrophy in. diversion colitis. Nutrition. 2004;20:197-199.
35. Geier MS, Butler RN, Howarth GS. Inflammatory bowel disease: current insight into pathogenesis and new therapeutic options: probioties prebiotics and sy.mbioties. Int J Food Microbiol. 2007; 115:1.-11.
36. Vernia P. Butyrate in the treatment of ulcerative colitis. Dig Liver Dis Suppl. 2007;1:27-30.
37. Goodlad RA, Lenton W, Ghatei MA, et al. Effects of an elemental diet, inert bulk and different types of dietary fibre on the response of the intestinal epithelium to refeeding in the rat and relationship to plasma gastrin, enteroglucagon, and PYY concentrations. Gut. 1987; 28:1.71-180.
38. 38. Frankel WL, Zhang W, Singh A, et al. Mediation of the trophic effects of short-chain fatty acids on the rat jejunum and colon. Gastroenterology. 1994;106:375-380. (Pubitemid 24041214)
39. Nasmyth DG, Godwin. PG, Dixon. MF, et al. Ileal ecology after pouch-anal anastomosis or ileostomy. A study of mucosal morphology, fecal bacteriology, fecal volatile fatty acids, and their interrelationship. Gastroenterology. 1989;96:817-824.
40. Galfi P, Bokori J. Feeding trial in. pigs with a diet containing sodium n-butyrate. Acta Vet Hung. 1990;38:3-17.
41. Piva A, Prandini A, Fiorentini L, et al. Tributyrin and lactitol synergestically enhanced the trophic status of the intestinal mucosa and reduced histamine levels in the gut of nursery pigs. J Anim Sci. 2002; 80:670-680.
42. Butzner JD, Parmar R, Bell CJ, et al. Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut. 1996:38: 568-573.
43. Gorbach SL, Banwell JG, Jacobs B, et al. Intestinal microflora in Asiatic cholera. I. "Rice-water" stool. J Infect Dis. 1970;121:32-37.
44. Chapman. MA, Grahn MF, Hutton. M, et al. Butyrate metabolism in the terminal ileal mucosa of patients with ulcerative colitis. Br J Surg. 1995;82:36-38.
45. 45. Roediger WE, Nance S. Selective reduction of fatty acid oxidation in colonocytes: correlation with ulcerative colitis. Lipids. 1990;25: 646-652. (Pubitemid 20370630)
46. de Coppet P, Thibault R, Bourreille A, et al. L'inflammation intestinale diminue l'expression du transporteur du butyrqte, MCT-I par les cellules epitheliales coliques. Gastroenterol Clin Biol. 2006;30:83.
47. 47. Reynolds DA, Rajendran VM, Binder HJ. Bicarbonate-stimulated [14C]butyrate uptake in basolateral membrane vesicles of rat distal colon. Gastroenterology. 1993;105:725-732. (Pubitemid 23249481)
48. 48. von. Engelhardt W, Burmester M, Hansen K, et al. Effects of amiloride and ouabain on short-chain fatty acid transport in guinea-pig large intestine. J Physiol. 1993;460:455-466. (Pubitemid 23058060)
49. Wächtershäuser A, Stein J. Rationale for the luminal provision of butyrate in intestinal, diseases. Eur J Nutr. 2000;39:164-171.
50. Fusunyan RD, Quinn JJ, Fujimoto M, et al. Butyrate regulates chemokine secretion by intestinal epithelial (Caco-2) cells through histone acetylation. Gastroenterology. 1998;114:A879.
51. Place RF, Noonan EJ, Giardina C. HDAC inhibition prevents NFkappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharmacol. 2005:70:394-406.
52. Fukae J, Amasaki Y, Yamashita Y, et al. Butyrate suppresses tumor necrosis factor alpha production by regulating specific messenger RNA degradation mediated through a cis-acting AU-rich element. Arthritis Rheum. 2005;52:2697-2707.
53. Segain JP, Raingeard de la Bletiere D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition; implications for Crohn's disease. Gut. 2000;47:397-403.
54. 54. Luhrs H, Gerke T, Schauber J, et al. Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate. Int. J Colorectal Dis. 2001;16:195-201. (Pubitemid 32700694)
55. Böhmig GA, Krieger PM, Säemann MD, et al. n-Butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by short-chain fatty acids. Immunology. 1997;92:234-243.
56. Agarwal VP, Schimmel EM. Diversion colitis: a nutritional deficiency syndrome? Nutr Rev. 1989;47:257-261.
57. Ramakrishna BS, Mathan VI. Colonic dysfunction in acute diarrhoea: the role of luminal short chain fatty acids. Gut. 1993;34:1215-1218.
58. 58. Ibrahim TM, Iheonunekwu N, Gill V, et al. Differentiating amoebic ulcero-haemorrhagic recto-colitis from idiopathic inflammatory bowel disease: still a diagnostic dilemma. West Indian Med J. 2005;54: 210-212. (Pubitemid 41335240)